Key Takeaways:
- The FDA has now authorized over 1,000 medical devices that incorporate AI or machine learning, across specialties such as radiology, cardiology, neurology, anesthesiology, dentistry, and orthopedics.
- Growth has been rapid: in 2015 only six devices were approved; by 2023 the number reached over 220, and today it stands at more than 1,000—reflecting exponential adoption.
- While the majority remain in diagnostic fields like radiology, emerging areas include AI-powered stethoscopes, wearable seizure monitors, dental diagnostic tools, and automated insulin systems.
The U.S. Food and Drug Administration has quietly crossed a significant milestone in 2025: over 1,000 medical devices powered by artificial intelligence or machine learning are now authorized for clinical use in the United States. This includes a wide array of tools supporting radiologists, cardiologists, neurologists, dentists, and chronic care professionals.
It’s a figure that might have seemed ambitious a decade ago. In 2015, only six AI-enabled devices had earned FDA clearance. Just eight years later, the agency had approved over 220, and that growth hasn’t slowed. The number nearly quadrupled between 2020 and 2025, tracking an estimated 45% compound annual growth rate. As of mid-2025, the tally has surpassed 1,000 devices, marking a tipping point where AI tools are no longer novelties in clinical workflows—they’re becoming essential components.
Radiology leads the way by a wide margin, accounting for more than 75% of FDA-cleared AI devices. This dominance is largely driven by image-based diagnostic systems that help identify tumors, brain bleeds, fractures, lung abnormalities, and more. Companies like GE Healthcare, Siemens Healthineers, Aidoc, and Canon have released multiple iterations of their AI diagnostic platforms, which increasingly serve as second-read or triage support tools in hospital settings. These platforms often assist in prioritizing urgent cases or helping to reduce error rates in high-volume imaging environments.
However, the AI medical device landscape is expanding well beyond radiology. Cardiology has emerged as a rapidly growing segment, with AI-enhanced tools now able to analyze electrocardiograms, support ultrasound interpretation, and even detect heart murmurs through advanced stethoscopes. Eko Health, for example, has developed FDA-cleared stethoscopes that use AI to screen for low ejection fraction, a precursor to heart failure, offering early intervention opportunities in primary care settings.
In neurology, the FDA has cleared seizure monitoring systems and stroke triage software that help clinicians identify emergent conditions more quickly. Wearable devices like Empatica’s wristband now offer real-time alerts for seizure events, helping patients and caregivers respond faster during crises.
Even dentistry—a field historically slower to adopt digital transformation—is beginning to show traction. AI software now assists in interpreting dental x-rays, helping identify cavities and root canal needs with reportedly higher accuracy than unaided clinicians. Smile Dx, one such product, is said to improve diagnostic precision by nearly 20% in general practice use.
What’s driving this explosion in AI medical approvals? Part of it is regulatory adaptation. The FDA has developed clearer pathways for Software as a Medical Device (SaMD) products, especially those built on machine learning models. Most of the currently approved tools fall into Class II—meaning they go through either 510(k) clearance or De Novo pathways depending on their novelty and risk profile.
Since 2019, the FDA has released a series of guidance documents outlining how AI tools can remain safe and effective across their learning life cycles. These include expectations for change management (when algorithms evolve after deployment), transparency in labeling, and mechanisms to maintain clinical performance over time. In short, the agency now has a playbook for balancing innovation with patient safety.
But growth brings complexity. As AI tools become more autonomous and pervasive in medical decisions, questions of trust, accountability, and validation become central. Tools must not only perform well in controlled environments but also deliver consistent, equitable outcomes across diverse populations and care settings.
Manufacturers are increasingly expected to show how their algorithms perform in real-world scenarios, not just in retrospective studies. This includes post-market surveillance, bias testing, and audit trails for transparency. At the same time, hospitals and health systems are being encouraged to establish governance boards or oversight frameworks to vet, monitor, and retrain AI tools that influence patient care.
For clinicians, the impact is mixed. Many welcome the added speed and consistency of AI tools—especially those that ease documentation, support triage, or screen patients for chronic conditions. Yet the influx of new tools also creates a learning curve. With over 1,000 devices now available, figuring out which ones are useful, reliable, and compatible with a specific clinical workflow is not always easy.
Looking ahead, AI in medical devices is poised to evolve from task-specific support tools to more integrated care companions. Devices that once performed narrow diagnostics may soon play broader roles in monitoring, risk stratification, and personalized treatment planning. There are already signs of this in diabetes management, where AI is helping to automate insulin delivery, and in chronic heart failure care, where wearable sensors are predicting patient decompensation before symptoms arise.
This shift raises both opportunity and responsibility. With broader autonomy comes the need for stronger safeguards, interdisciplinary validation, and patient engagement. As tools begin to operate with greater independence, it will be crucial that they remain explainable and accountable—not just accurate.
Still, the trajectory is clear. Artificial intelligence is no longer just “coming to healthcare.” It’s here, embedded in tools that scan your chest X-ray, review your dental images, assess your ECG, or monitor your chronic condition overnight. The FDA’s 1,000-device milestone represents a quiet but powerful signal that AI in medicine has entered a new phase: widespread clinical relevance.
Learn how AI Agents can supercharge your company’s profits and productivity at TMC’s AI Agent Event in Sept 29-30, 2025 in DC.
Rich Tehrani serves as CEO of TMC and chairman of ITEXPO #TECHSUPERSHOW Feb 10-12, 2026 and is CEO of RT Advisors and is a Registered Representative (investment banker) with and offering securities through Four Points Capital Partners LLC (Four Points) (Member FINRA/SIPC). He handles capital/debt raises as well as M&A. RT Advisors is not owned by Four Points.
The above is not an endorsement or recommendation to buy/sell any security or sector mentioned. No companies mentioned above are current or past clients of RT Advisors.
The views and opinions expressed above are those of the participants. While believed to be reliable, the information has not been independently verified for accuracy. Any broad, general statements made herein are provided for context only and should not be construed as exhaustive or universally applicable.
Portions of this article may have been developed with the assistance of artificial intelligence, which may have contributed to ideation, content generation, factual review, or editing.
